- Home
- PBYI vs DHF Comparison
PBYI vs DHF Comparison
Compare PBYI & DHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- DHF
- Stock Information
- Founded
- PBYI 2010
- DHF 1998
- Country
- PBYI United States
- DHF United States
- Employees
- PBYI N/A
- DHF N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- DHF Finance Companies
- Sector
- PBYI Health Care
- DHF Finance
- Exchange
- PBYI Nasdaq
- DHF Nasdaq
- Market Cap
- PBYI 152.4M
- DHF 172.4M
- IPO Year
- PBYI N/A
- DHF N/A
- Fundamental
- Price
- PBYI $3.28
- DHF $2.51
- Analyst Decision
- PBYI Strong Buy
- DHF
- Analyst Count
- PBYI 1
- DHF 0
- Target Price
- PBYI $7.00
- DHF N/A
- AVG Volume (30 Days)
- PBYI 375.3K
- DHF 451.1K
- Earning Date
- PBYI 05-08-2025
- DHF 01-01-0001
- Dividend Yield
- PBYI N/A
- DHF 7.65%
- EPS Growth
- PBYI 143.51
- DHF N/A
- EPS
- PBYI 0.77
- DHF N/A
- Revenue
- PBYI $232,709,000.00
- DHF N/A
- Revenue This Year
- PBYI N/A
- DHF N/A
- Revenue Next Year
- PBYI N/A
- DHF N/A
- P/E Ratio
- PBYI $4.25
- DHF N/A
- Revenue Growth
- PBYI 2.68
- DHF N/A
- 52 Week Low
- PBYI $2.23
- DHF $2.06
- 52 Week High
- PBYI $4.13
- DHF $2.39
- Technical
- Relative Strength Index (RSI)
- PBYI 52.36
- DHF 56.22
- Support Level
- PBYI $3.14
- DHF $2.45
- Resistance Level
- PBYI $3.45
- DHF $2.54
- Average True Range (ATR)
- PBYI 0.19
- DHF 0.02
- MACD
- PBYI 0.01
- DHF -0.00
- Stochastic Oscillator
- PBYI 51.19
- DHF 57.14
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. It invests predominantly in fixed-income securities of below-investment-grade credit quality.